Key Drivers
- Gross Margin
- Leverage Rising
- Cash Burn
AIAI Summary
AXSM has shifted from a speculative CNS pipeline bet to a real commercial growth story with AUVELITY/SUNOSI momentum and an Alzheimer's agitation catalyst, but the key question is whether it can turn that revenue growth and 92%+ gross margins into operating leverage before cash burn and rising leverage strain the balance sheet.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Leverage Rising
- •Cash Burn
AXSM has excellent gross margins and decent liquidity, but persistent operating losses, negative cash flow, rising leverage, and a rich valuation make the stock risky despite strong product economics.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Lower Highs
- •Range Bound
AXSM remains modestly upward over the last month, but repeated buying near $237-$241 and lower highs below $250-$255 point to consolidation unless it reclaims $250.
Failed to hold the $255.17 peak and has since drifted into lower highs
Sentiment & News
Key News Insights:
- •Auvelity launch
- •Sleep pipeline progress
- •ADHD trial start
Axsome Therapeutics is rapidly expanding its CNS franchise through Auvelity's Alzheimer's agitation launch, new sleep/ADHD trial data, and ongoing late-stage pipeline momentum, keeping investor focus on continued growth.
These developments strengthen Axsome's growth narrative and may support sentiment as the company advances multiple high-value CNS programs
Similar Companies in Healthcare
Other companies in the same sector with AI ratings